Skip to main content
main-content

01.12.2021 | Research article | Ausgabe 1/2021 Open Access

BMC Infectious Diseases 1/2021

Use of T-SPOT.TB for the diagnosis of unconventional pleural tuberculosis is superior to ADA in high prevalence areas: a prospective analysis of 601 cases

Zeitschrift:
BMC Infectious Diseases > Ausgabe 1/2021
Autoren:
Xinting Yang, Jing Zhang, Qingtao Liang, Liping Pan, Hongfei Duan, Yang Yang, Hua Li, Chao Guo, Qi Sun, Hongyan Jia, Boping Du, Rongrong Wei, Aiying Xing, Zongde Zhang, Xiaoyou Chen
Wichtige Hinweise
Xinting Yang, Jing Zhang and Qingtao Liang contributed equally to this work.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abbreviations
AFB
Acid-fast bacilli
ADA
Adenosine deaminase
AUC
Area under the curve
BMI
Body mass index
CRS
Composite reference standard
CI
Confidence interval
CFP-10
Culture filtrate protein-10
DOR
Diagnostic odds ratio
ESAT-6
Early secretory antigenic target-6
ELISPOT
Enzyme-linked immunosorbent spot
ECDC
European Centre for Disease Prevention and Control
IGRA
Interferon gamma release assay
IFN-γ
Interferon gamma
IQR
Interquartile range
LDH
Lactate dehydrogenase
+LR:
Positive likelihood ratio
-LR
Negative likelihood ratio
MTB
Mycobacterium tuberculosis
NPV
Negative predictive value
OR
Odds ratio
PB
Peripheral blood
PBMCs
Peripheral blood mononuclear cells
PE
Pleural effusion
PFMCs
Pleural fluid mononuclear cells
PF
Pleural fluid
PPV
Positive predictive value
ROC
Receiver operating characteristic
SFCs
Spot-forming cells
TB
Tuberculosis
TPE
Tuberculous pleural effusion
WHO
World Health Organization

Background

Tuberculous pleural effusion (TPE), one of the most common forms of extrapulmonary TB, has a presentation spectrum from fully absorbed benign to complicated pleural thickening and even serious complications such as empyema and fibrothorax, which may have a lasting effect on lung function. Early and effective diagnosis could minimize hospital days and maximize quality of life. At present, the most direct evidence for Mycobacterium tuberculosis (MTB) infection is aetiology [ 1], which has suboptimal sensitivity. Therefore, patients whose pleural effusion is characterized by lymphocytic exudates [ 2] combined with high ADA levels are frequently diagnosed as having TPE by clinicians, resulting in high prevalence.
Adenosine deaminase (ADA), an enzyme produced from lymphocytes that is involved in purine metabolism, has been used in the diagnosis TPE for a long time due to its excellent sensitivity and specificity [ 3, 4]. However, recent studies have shown that patients with empyema, malignancy, or rheumatoid pleurisy can also have high ADA levels [ 5], and negative results in older TPE patients [ 6] and fluctuation were obviously affected by the patient profile and local tuberculosis (TB) prevalence [ 7].
The interferon gamma release assay (IGRA) is a commercially available cost-effective assay that detects changes in interferon gamma (IFN-γ) caused by MTB infection. The WHO guidelines [ 8] rejected the recommendation of the IGRA for differentiating active TB, especially in high-burden countries, but the guidelines published by the European Centre for Disease Prevention and Control (ECDC) [ 9] proposed that the IGRA could contribute supplementary information for patients who test negative for acid-fast bacilli (AFB) and MTB culture in sputum. In recent years, an increased number of studies have researched the utility of the IGRA to diagnose TPE. A recent meta-analysis [ 10] assessing the performance of the IGRA for diagnosing TPE exhibited satisfactory outcomes (PPV = 82%, NPV = 87%), but the results were heterogeneous (I 2 = 92.0–82.5%), suggesting that the results are still controversial and polarizing. Theoretically, tuberculosis antigen-specific responses by IGRA should provide a discriminatory value superior to non-specific inflammatory biomarkers (e.g., unstimulated IFN-γ or ADA), but this is not the case. We boldly presume that the superiority of the IGRA could be concealed by discrepancies in population characteristics, causing inconsistencies between studies.
Currently, there are two commercial kits for IGRA; one is an enzyme-linked immunosorbent assay (ELISA), which detects the IFN-γ in the whole blood and is represented by the QuantiFERON-TB Gold test [ 9], which was approved by the FDA in 2004; the other test is the enzyme-linked immune-spot assay (ELISpot), which detects IFN-γ released by mononuclear cells isolated from whole blood under the stimulation of specific antigen, represented by the T-SPOT assay [ 9] developed by Oxford University. Both methods have similar principles, but they are slightly different in detection technology and concrete operation. To further to clarify the diagnostic role of the IGRA for TPE in patients with a high TB burden, this prospective study was conducted to investigate the utility of the IGRA assay (T-SPOT.TB) in the discrimination of TPE and to compare the difference in potency with ADA in TPE subjects with different characteristics.

Methods

Participant population and study procedure

A prospective study was performed at Beijing Chest Hospital, Capital Medical University, from June 2015 to October 2018, in which all suspected pleural effusion (PE) patients were enrolled consecutively. The enrolled patients met the following criteria: (1) age ≥ 14 years; (2) presentation with PE on chest ultrasonic examinations; and (3) tolerated thoracic puncture and had more than 100 ml pleural effusion. The exclusion criteria were as follows: (1) HIV positive; (2) a history of immunodeficiency, autoimmune disease or use of immunosuppressive drugs; and (3) previous anti-tuberculosis treatment for more than 2 weeks.
Clinical samples (including sputum, peripheral blood (PB) and pleural fluid (PF)) from all participants were processed for diagnostic purposes after obtaining written informed consent (P.S. The consent of the participants below age 18 years were obtained from their guardian); tests included routine clinical biochemical testing for each PF sample, which contains total protein, glucose, lactate dehydrogenase (LDH) and ADA, and smear microscopy, culture and Gene-Xpert for each sputum and PF sample. All participants’ clinical data were extracted by the investigators, and the treatment process and discharge diagnoses were tracked. All participants were followed up for 12 months to verify the final diagnosis, and patients with negative outcomes after anti-TB treatment in the last 12 months were deemed indeterminate diagnoses.

Clinical categories of pleurisy

Patients were divided into three groups according to the composite reference standard (CRS), which was composed of clinical, laboratory, and radiological examinations and follow-up data of diagnostic treatment. (1) Bacteriologically confirmed TPE was represented by the isolation of MTB in PE, sputum or pleural tissue by culture, microscopy or Gene-Xpert, or a pleural biopsy that demonstrated caseating granulomas. (2) Probable TPE lacked bacteriological confirmation, but all patients were treated empirically for TB based on clinical suspicion (e.g., typical clinical symptoms, remarkable radiological imaging and positive outcome of anti-TB treatment during follow-up). (3) Non-TPE indicated cases were diagnosed definitively as other diseases, such as malignancy or empyema (non-tuberculous disease).

ADA measurement

ADA activity was determined colorimetrically at 37°C using a commercial kit (Adenosine Deaminase Assay Kit; Beijing Strong Bio-technologies, Beijing, China) according to the peroxidase assay [ 11]. One unit of ADA was defined as the amount of enzyme that generated one micromole of inosine from adenosine per minute at 37°C. The results were expressed in international units per litre of PE (IU/L).

T-SPOT.TB in PF and PB

The PB (4 mL) and PF (45 mL) samples collected from each participant were tested within 6 h. The PB samples were diluted 1-fold and centrifuged at 900 g for 20 min, and the PF samples were centrifuged at 500 g for 10 min. The supernatant of both samples was discarded for T-SPOT.TB testing.
The T-SPOT.TB assay was conducted following the manufacturer’s instructions (Oxford Immunotec Ltd., Oxford, UK), which were identical for both the PB and PF samples. The pellets were resuspended in 8 mL of AIM-V medium (GIBCO, Rockville, MD, USA). Briefly, mononuclear cells (MCs) were separated using FicolleHypaque, washed, resuspended, and counted. Empty wells were used as negative controls, the T lymphocyte mitogen phytohemagglutinin was used as a positive control, and the ESAT-6 and CFP-10 peptides were in separate wells. Isolated peripheral blood mononuclear cells (PBMCs) and pleural fluid mononuclear cells (PFMCs) were added to the wells (2.5 × 10 5 cells per well) that were precoated with a monoclonal antibody against IFN-γ and incubated at 37 °C for 16 to 20 h. The spot-forming cells (SFCs) were read using an automated enzyme-linked immunosorbent spot (ELISPOT) reader (CTL-ImmunoSpotS5 Versa Analyser). A test was considered valid when the positive control > 20 SFCs/10 6 mononuclear cells and the negative control < 6 SFCs/10 6 mononuclear cells. The final SFCs of ESAT-6 or CFP-10 were defined as ESAT-6 or CFP-10 SFCs minus negative control SFCs. The Max SFCs of the T-SPOT assay were defined as the larger of the final ESAT-6 and CFP-10 SFCs.

Diagnosis

Smear, acid-fast bacilli (AFB) and mycobacterial culture

Specimens including sputum and PF (5 mL) were prepared for direct smear and stained with auramine and examined by light-emitting diode microscopy. The smear was read and interpreted in accordance with the WHO guidelines [ 12]. The sputum and PF (5 mL) were preprocessed using N-acetyl-L-cysteine and sodium hydroxide (NALC-NaOH) and centrifuged, and the supernatant was discarded. The resuspended pellet was transferred to solid Lowenstein-Jensen medium (Encode Medical Engineering Co., Ltd., China) and liquid medium and subjected to culture in a mycobacterial growth indicator tube (MGIT) 960 system (Becton, Dickinson and Company, USA). The presence of the MTB complex in any medium represented positive MPT64 antigen testing. The positive events and time were recorded.

Gene-Xpert

The Gene-Xpert test was performed according to the manufacturer’s instructions (Cepheid, Sunnyvale, CA, USA). Briefly, the specimen (including sputum and concentrated PF) and sample reagent were fully premixed at room temperature. The final 2 ml mixture was collected and transferred to the cartridge and loaded into the automatic Gene-Xpert instrument. Duplicate testing was performed on samples with an invalid result.

Statistical analysis

Data were analysed using IBM SPSS 25.0 (SPSS Inc. Chicago, IL, USA) GraphPad Prism 8.2.1 (GraphPad Software, Inc. La Jolla, USA). Quantitative variables are presented as the mean ± standard deviation (SD) or median (interquartile range (IQR)), and categorical variables are presented as frequencies (percentages). To identify differences between two independent groups, the chi-square test was used to detect differences between categorical variables, and the Mann-Whitney U test and unpaired t-test were used for continuous data in non-normal or normal distributions, respectively. A result was considered statistically significant when the P-value was < 0.05.
Receiver operating characteristic (ROC) curves were plotted to evaluate the diagnostic performance of ADA and T-SPOT.TB, obtaining the optimal cut-off value and calculating the corresponding areas under the ROC curve (AUCs). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (+LR), negative likelihood ratio (−LR), diagnostic odds ratio (DOR) and accuracy were calculated.
Predictors that were related to TPE by a predetermined P-value of 0.10 or less were selected and used in a multivariable logistic regression model (except symptoms). Stepwise backward selection using P < 0.10 was used to derive the model. Multicollinearity was assessed, and variables contributing to the best fit of the final model, or most related and widely available in our setting, were retained in the final model. For application of the model, a bioclinical score chart was derived using the adjusted OR value of the predictors [ 13]. Overall research was completed in keeping with the Standards for Reporting of Diagnostic Accuracy (STARD) template [ 14].

Results

Participant characteristics

From June 2015 to October 2018, a total of 601 suspected PE patients were enrolled, and patients with indeterminate diagnoses ( n = 16) and unverifiable patient details ( n = 9) and those who were age < 14 years old ( n = 1) and lost to follow-up ( n = 4) were excluded. According to the CRS, 145 patients had confirmed TPE, 252 patients had clinically diagnosed probable TPE, and 174 patients had non-TPE (Fig.  1). Among the 174 non-TPE patients, 117 (67.2%) were diagnosed with malignant pleural effusion, 32 (18.4%) with parapneumonia or empyema (non-tuberculous), 8 (4.6%) with exudation effusion (non-tuberculous), 4 (2.3%) with transudate effusion and 13 (7.5%) with other conditions (Fig. 1), which was in line with the current epidemiology of PE.
In the confirmed TPE group, the tests of sputum for AFB, culture, Gene-Xpert were positive in 27.6, 60.5 and 64.6% of patients, respectively, while PF was positive in only 2.2, 37.4 and 25.4% of patients, respectively, and a higher total detection rate in sputum (68.3% vs. 46.9%) showed that obtaining direct proof of MTB infection from PF is more difficult than from sputum (Table 1).
Table 1
Laboratory bacterial-positive percentage of diagnosis of TPE
Positive TB test
Confirm TPE ( n = 145)
Sputum
 Smear, AFB positive
35/127
 Culture positive for MTB
72/119
 Gene-xpert positive
73/113
 Total positive tests
99/145
Pleural fluid
 Smear, AFB positive
3/137
 Culture positive for MTB
52/139
 Gene-xpert positive
36/142
 Total positive tests
68/145
Data are presented as frequency (percentage)
AFB Acid-fast bacilli, MTB Mycobacterium tuberculosis, TB tuberculosis, TPE tuberculous pleural effusion

Clinical, demographic and biochemical data

The demographic and clinical characteristics of all participants are summarized in Table 2. The patients in the TPE group were younger than those in the non-TPE group (42.15 ± 19.78 vs. 57.59 ± 15.36, P < 0.001), and there were more male subjects in the TPE group than the non-TPE group (75.3%, 299/397 vs. 59.2%, 103/174, P < 0.001) and males were predominant in unilateral PE (83.9%, 333/397). All features were in accordance with the clinical patterns of TPE [ 15]. According to BMI in Table 2, The patients in the TPE group was significantly thinner than the non-TPE group’s (21.70 ± 4.24 vs. 23.23 ± 3.37, P < 0.001). Patients with TPE more frequently presented with fever (74.8% vs. 39.7%, P < 0.001) but had less chest tightness (58.6% vs. 71.8%, p = 0.013) than patients without TPE. The patients with probable TPE inferred by clinicians had more obvious clinical symptoms relating to TB infection, such as more night sweats (21.4% vs. 10.3%, P = 0.009), more weight loss (34.1% vs. 23.6%, P = 0.042) and less haemoptysis (l.2% vs. 7.5%, P < 0.001). However, there were no significant differences in various characteristics between the confirmed and probable TPE groups ( P > 0.05).
Table 2
Descriptive characteristics of participants ( N = 571)
 
Non-TPE
( n = 174)
TPE patients ( n = 397)
*P value
Confirm TPE ( n = 145)
% P value
Probable TPE ( n = 252)
§ P value
Age, ys (Mean ± SD) ± sd) sdSD)
57.59 ± 15.36
45.00 ± 20.71
< 0.001 #
40.5 ± 19.07
< 0.001 #
< 0.001 #
Gender(%)male
103 (59.2)
119 (82.1)
< 0.001
180 (71.4)
0.009
< 0.001
BMI (kg/m 2)
23.23 ± 3.37
21.40 ± 7.43
0.004
21.88 ± 3.30
< 0.001
< 0.001
Onset time (day)
35 (20–90)
30 (14–60)
0.033 #
21.50 (13.65–45.71)
< 0.001 #
< 0.001 #
Smoking
 None
107 (61.5)
91 (62.8)
0.817
164 (65.1)
0.450
0.532
 Years of smoking
30.79 (20.25–41.73)
21.67 (7.67–33.33)
0.259 #
13.67 (8.53–28.64)
0.038 #
0.050 #
 Previous anti-TB treatment
31 (17.8)
44 (30.3)
0.009 #
36 (14.3)
0.325
0.516 #
Symptoms
 Fever
69 (39.7)
117 (80.7)
< 0.001
180 (71.4)
< 0.001
< 0.001
 Cough
131 (75.3)
120 (82.8)
0.105
191 (75.8)
0.905
0.422
 Chest pain
76 (43.7)
73 (50.3)
0.235
126 (50.0)
0.199
0.156
 Chest tightness
125 (71.8)
85 (58.6)
0.013
190 (75.4)
0.411
0.537
 Night sweat
18 (10.3)
22 (15.2)
0.195
54 (21.4)
0.003
0.009
 Weight loss
41 (23.6)
41 (28.3)
0.338
86 (34.1)
0.019
0.042
 Hemoptysis
13 (7.5)
3 (2.1)
0.057
3 (1.2)
0.002
< 0.001
Effusion site
 Left
66 (37.9)
56 (38.6)
0.900
93 (36.9)
0.830
0.928
 Right
69 (39.7)
65 (44.8)
0.351
119 (47.2)
0.122
0.138
 Bilateral
39 (22.4)
24 (16.6)
0.190
40 (15.9)
0.088
0.072
Pleural effusion volume
 Small
72 (41.6)
59 (40.7)
0.867
106 (42.1)
0.927
0.990
 Moderate
52 (30.1)
42 (29.0)
0.832
66 (28.0)
0.382
0.486
 Massive
49 (28.3)
44 (30.3)
0.693
81 (32.1)
0.410
0.451
 Total protein(g/L)
34.36 ± 18.68
37.63 ± 19.57
0.003 #
43.47 ± 14.56
< 0.001 #
< 0.001 #
 Glucose (mmol/L)
5.81 ± 2.92
4.50 ± 2.36
< 0.001 #
5.04 ± 2.17
< 0.001 #
< 0.001 #
 LDH(U/L)
256 (158.25–482)
425 (276–704)
< 0.001 #
377.5 (240.5–580.75)
< 0.001 #
< 0.001 #
 ADA (IU/L)
11.8 (8.25–18.65)
50 (37.85–62.15)
< 0.001 #
45 (31.875–57.9)
< 0.001 #
< 0.001 #
Data are presented as mean ± standard deviation (SD), median (interquartile ranges) or frequency (percentage)
TPE tuberculous pleural effusion, BMI body mass index, TB tuberculosis, LDH lactate dehydrogenase, ADA adenosine deaminase
%Comparisons were performed between confirm- and non- TPE group using chi-square test and #Mann–Whitney U test and ¶unpaired t-test
§Comparisons were performed between non- and probable- TPE group using chi-square test and #Mann–Whitney U test and ¶unpaired t-test
*Comparisons were performed between non TPE and TPE group using chi-square test and #Mann–Whitney U test and ¶unpaired t-test
Through multivariate logistic regression analysis, age (< 45 yrs.; OR = 5.61, 95% confidence interval (CI) 3.59–8.78; P < 0.001), gender (male; OR = 2.68, 95% CI 1.75–2.88; P < 0.001) and BMI (< 22; OR = 1.93, 95% CI 1.30–2.88; P = 0.001), were included in the final model and were independently associated with the risk of TB (Table 3).
Table 3
Logistic regression analysis of risk factors for TPE
 
Adjusted OR(95%CI)
P value
Gender
 Male
2.68 (1.75–4.11)
< 0.001
 Female
1.00
 
BMI
  < 22
1.93 (1.30–2.88)
0.001
 ≧22
1.00
 
Age
  < 45y
5.61 (3.59–8.78)
< 0.001
 ≧45y
1.00
 
BMI body mass index, OR odds radio

Diagnostic utility of the T-SPOT.TB assay for PB and PF

As shown in Fig.  2, the final ESAT-6 and CFP-10 and Max SFCs for PB and PF were affirmed to discriminate TPE from non-TPE, and no significant differences were observed between confirmed and probable TPE. In Table 4, we show the cut-off value of PB derived from the ROC analysis between the confirmed TPE group and the non-TPE group (Fig. 2), which is extremely close to the positive cut-off value (24 SFCs/10 6 mononuclear cells) provided by the manufacturer. Overall, when we used the same cut-off value of 22 SFCs/10 6 mononuclear cells, the performance of ESAT-6 was slightly better than that of CFP-10 in PB, with an AUC of 0.840 vs 0.796 ( P = 0.055), as well as a sensitivity of 82.1% vs 75.2% ( P = 0.123) and a specificity of 75.3% vs 77.9% ( P = 0.847). However, when considering Max SFCs (cut-off value =22 SFCs/10 6 mononuclear cells), the AUC, sensitivity and specificity were 0.839 (95% CI 0.794–0.884), 90.3 and 67.2%, respectively, which were no better than those of ESAT-6 ( P = 0.954) (Table 4).
Table 4
Diagnostic utility of T-SPOT.TB (PF & PB) and ADA for diagnosing TPE
Variables
Cut-off value a
Sensitivity%
Specificity%
PPV%
NPV%
+LR
-LR
DOR
AUC
95%CI
Peripheral blood (PB)
 ESAT-6
24 #
77.9
77.0
73.9
80.7
3.39
0.29
11.80
   
22¶
82.1
75.3
73.5
83.4
3.32
0.24
13.98
0.840
0.794–0.878
 CFP-10
24 #
72.4
74.7
70.5
76.5
2.86
0.37
7.75
   
22¶
75.2
74.7
71.2
78.3
2.97
0.33
8.95
0.796
0.747–0.839
 Max SFCs
24 #
86.9
69.0
70.0
86.3
2.80
0.19
14.77
   
22¶
90.3
67.2
69.7
89.3
2.75
0.14
19.07
0.839
0.794–0.884
Pleural fluid (PF)
 ESAT-6
170¶
86.9
78.2
76.8
87.7
3.99
0.17
23.80
0.874
0.833–0.909
 CFP-10
142¶
85.5
73.6
72.9
85.9
3.24
0.20
16.44
0.857
0.813–0.894
 Max SFCs
466¶
81.4
82.8
79.7
84.2
4.73
0.22
21.07
0.885
0.846–0.923
 ADA
22.4¶
89.0
83.9
82.2
90.1
5.53
0.13
42.16
0.887
0.847–0.920
 
40
71.0
93.1
89.6
79.4
10.29
0.31
33.03
   
ADA adenosine deaminase, TPE tuberculous pleural effusion, NPV negative predictive value, PPV positive predictive value, +LR positive likelihood ratio, −LR negative likelihood ratio, DOR diagnostic odds ratio, SFCs spot-forming cells, Max the larger of ESAT-6 and CFP-10, AUC the are under curve
#: manufacturer derived cut-off point for PB; ¶: AUC derived cut-off point
a Values are expressed as IU/L for ADA, and as SFCs/106 mononuclear cells for T-SPOT
As expected, the performance of the PF T-SPOT assay was distinctly improved compared to the PB T-SPOT assay. ESAT-6- and CFP-10-specific cells were more highly concentrated in PF than in PB, with median ratios of 12.13 (IQR 3–29.4) and 9.30 (IQR 1.22–30.15), respectively, in the confirmed TPE group and median ratios of 11.87 (IQR 3.96–35.15) and 10.60 (IQR 2.63–32.21), respectively, in the probable TPE group, and no significance was observed between any groups. Based on the ROC analysis, the optimal cut-off point was 170 for PF ESAT-6, which produced a sensitivity of 86.9% and specificity of 78.2%, and the optimal cut-off point was 142 for PF CFP-10, which produced a sensitivity of 85.5% and specificity of 73.6%. Max SFCs in PF exhibited the best diagnostic efficiency, which was equal to ADA (0.885 vs 0.887, P = 0.957), with a sensitivity of 83.0% and a specificity of 83.1%, corresponding to a cut-off value of 466 SFCs/10 6 mononuclear cells (Fig. 2, Table 4).

Comparison of the diagnostic utility of ADA and the T-SPOT.TB assay stratified by bioclinical score

The median ADA levels in the non-TPE, confirmed TPE and probable TPE groups were 11.8 IU/L (IQR 8.25–18.65), 50 IU/L (IQR 37.85–62.15), and 45 IU/L (IQR 31.875–57.9), respectively (Table 2), confirming that a low ADA level was satisfactory in excluding TPE, but the ADA level in the probable TPE group was slightly lower than that in the confirmed TPE group ( P = 0.055).
Each participant was grouped by scoring the logistic regression coefficient [ 16]. As shown in Table 5, when the score = 11 and the three risk factors were met (< 45 yrs., male and BMI < 22), the performance of PF T-SPOT was noninferior to ADA; compared to the stable utility of the PF T-SPOT assay, the sensitivity of ADA was positively related to score decline, while specificity was negatively related, suggesting that the PF T-SPOT assay performed better than ADA in unconventional patients, especially when the score = 0 (representing female patients whose age was more than 45 yrs. and BMI ≥ 22). The PF T-SPOT assay had a noninferior specificity (84.4% vs. 96.9%, P = 0.370) and a superior sensitivity (76.5% vs. 23.5%, P = 0.016) compared to ADA.
Table 5
Performance outcomes of a bioclinical score for ADA and T.SPOT
Score
(non: TPE)
Assay
(cut-off value a)
Sensitivity
Specificity
PPV
NPV
Accuracy
§X 2
§ P value
¶X 2
P value
 
ADA(40)
23.5
96.9
80.0
70.5
71.4
5.82
0.016
0.80
0.370
0
(32:17)
PB T.SPOT(24)
76.5
62.5
52.0
83.3
67.3
       
 
PF T.SPOT(466)
76.5
84.4
72.2
87.1
81.6
       
2
ADA(40)
51.0
94.4
92.9
57.1
68.7
21.42
< 0.001
7.26
0.006
 
PB T.SPOT(24)
79.4
64.5
76.4
68.3
73.3
       
/3/5
(107:155)
PF T.SPOT(466)
76.1
80.4
84.9
69.9
77.9
       
6/8/9
ADA(40)
73.2
86.7
95.9
43.3
75.8
10.26
0.001
0.14
0.705
(30:127)
PB T.SPOT(24)
93.7
93.3
98.3
77.8
93.6
       
 
PF T.SPOT(466)
89.8
90.0
97.4
67.5
89.8
       
 
ADA(40)
81.6
80.0
98.8
18.2
81.6
0.04
0.840
0
> 0.999
11
(5:98)
PB T.SPOT(24)
85.7
60.0
97.7
17.6
84.5
       
 
PF T.SPOT(466)
80.6
80.0
98.8
17.4
79.0
       
ADA adenosine deaminase, BMI body mass index, TPE tuberculous pleural effusion, NPV negative predictive value, PPV positive predictive value
Age < 45 yrs., male and BMI < 22 scored 6, 3, 2 points, respectively
§Comparisons were performed for sensitivity between ADA and PF T.SPOT using chi-square test
¶ Comparisons were performed for specificity between ADA and PF T.SPOT using chi-square test
a Values are expressed as IU/L for ADA, and as SFCs/10 6 mononuclear cells for T-SPOT.Data are presented as percentage

Comparison of the diagnostic utility of ADA and T-SPOT.TB stratified by age

In Fig.  3a, the scatter plot shows that the distribution of ADA levels in the TPE group shifted downwards ( P < 0.05) from age 40 years and above, especially the median ADA level in patients over 60 years old, which was lower than the clinical diagnostic point (40 IU/L), indicating that the ADA activity level was significantly negatively correlated with increasing age ( P < 0.001); notably, the performance of the PF T-SPOT assay at different age stages was steady, with no significant differences among all groups ( P = 0.604) (Fig. 3b). The above results showed that the performance of the T-SPOT.TB assay was superior to ADA in older patients.

Diagnostic utility of the T-SPOT.TB assay in patients with indeterminate ADA (ranging from 20 to 40)

In our study, the cut-off value of ADA derived from ROC analysis was 22.4 IU/L, which had higher sensitivity (89.0%); conversely, when an ADA value of more than 40 IU/L was recognized as positive (international recommendations), it produced a higher specificity (93.1%). Therefore, we had 112 patients (19.6%) with ADA values ranging from 20 to 40 IU/L (21 in non-TPE, 26 in confirmed TPE, 65 in probable TPE),which were designated as ADA indeterminate. In Fig.  4, the scatter plot shows the diagnostic utility of the PF T-SPOT assay in the indeterminate analysis. The sensitivity, specificity, PPV and NPV were 87.9, 90.5, 97.6 and 63.3%, respectively. The Youden index was 0.784, and the sensitivity, specificity, PPV and NPV of the PB T-SPOT assay were 83.5, 76.2, 93.8 and 51.6%, respectively. The Youden index was 0.597. These data indicated that the T-SPOT.TB assay could discriminate TPE patients with an ADA value ranging from 20 to 40 IU/L, and the utility of the T-SPOT assay in PF was superior to that in PB.

Discussion

To the best of our knowledge, although there are several publications that evaluate the utility of the T-SPOT assay for the diagnosis of TPE [ 9, 10], the majority of studies recruited a small sample population ( n < 100) for evaluation, and the results were conflicting. Our study provided the largest cohort (TPE:non-TPE = 397:145) to date, confirming the value of the T-SPOT assay for the diagnosis of TPE with high confidence and providing specific reference suggestions for the clinical application of the T-SPOT assay.
In this study, all suspected PE participants had been consecutively, unselectively enrolled, and all TPE patients had a definite diagnosis by bacteriological confirmation or positive outcome for anti-TB therapy, which highly reflects the demographic epidemiological characteristics of tuberculosis-prone areas. The recruited samples ranged from adolescents to elderly patients over 90 years of age, confirming again that the TPE patients had the clinical characteristics of younger males, combined with higher ADA activity and higher T-SPOT response for PF and PB. Comprehensively, the specificity of the T-SPOT assay for PF was much higher with approximate sensitivity than that for PB, which is similar to other studies [ 17]. Moreover, different from the low incidence areas where the cut-off of PF T-SPOT was equal to PB T-SPOT’s [ 18, 19], our research affirmed that the diagnostic cut-off obtained from PB was not the optimal for PF in the high prevalence areas, and PFs’ cut-off was much higher than PB,which was in line with the expectation of another high-burden settings, for example, 300 SFCs/10 6 mononuclear cells in Korea [ 20].
ADA, the most common biomarker for the diagnosis of TB pleurisy, has a value of more than 40 IU/L in lymphocyte-dominated PE and carries a PPV of 98% in high TB endemic regions [ 3, 4], while a retrospective analysis on ADA in 1637 subjects obtained an NPV of 100% with less than 15.0 IU/L [ 21]. In our study, we found that recognizing > 40 IU/L as the sole indicator of TPE may not be the most suitable approach, as it obtained high specificity while sacrificing sensitivity; 35.5% (141/397) of TPE patients had an ADA level that was lower than 40 IU/L in this study, 29.8% of which had a definite aetiological basis. In addition, the utility of a cutoff of 22.4 IU/L derived from ROC analysis was better than 40 IU/L (Youden index 0.729 vs. 0.641), this situation was similar to the publication of Santos et al. [ 22]. However, when comprehensively considering the non-specific elevation of ADA levels caused by non-tuberculosis inflammatory PE [ 19] (particularly complicated parapneumonic effusions and empyemas) and lymphomas, patients whose ADA was more than 20 IU/L and less than 40 IU/L were classified as indeterminate ADA. Conversely, the PF T-SPOT assay showed excellent diagnostic utility between ADA indeterminate groups, and its accuracy was higher than 90.2%, and we predict that the result of the PF T-SPOT assay could be a considerable indicator for highly suspected TPE patients with indeterminate ADA.
Many previous studies [ 23, 24] indicated that the performance of diagnosing TPE for patients aged more than 45 yrs. is still unknown. A recent study found that only 4.65% of elderly TPE subjects had levels over 40 IU/L [ 25]. Our research fully demonstrated this phenomenon simultaneously. In addition, we observed that the unclear boundary influenced by age for ADA was opportunely concentrated in the ADA indeterminate groups. Among the patients in the ADA indeterminate group, 85.7% (18/21), 73.7% (19/26) and 47.7% (31/65) of patients aged more than 45 yrs. were in the non-TPE, confirmed TPE and probable TPE groups, respectively, while the superior performance of the PF T-SPOT assay in distinguishing between ADA indeterminate groups may be explained by its steady performance in all age groups, in addition to interference with ADA by other inflammatory aetiologies. Nevertheless, ADA is a widely used biomarker for screening TPE due to its simplicity, rapidity, and low financial cost, but the above results proved that overreliance on ADA differentiation may lead to missed diagnosis/misdiagnosis in clinical settings, especially in the indeterminate range. In addition, the PF T-SPOT assay could fill this gap.
In addition to age, we screened two additional high-risk factors that were significantly related to TPE, sex and BMI. There were 5 non-TPE patients scoring 11 (simultaneously having three high-risk factors: age < 45 yrs., male sex and BMI < 22), which directly demonstrated that these clinical characteristics could be an effective reference index for discerning TPE from other PEs. We often defined these patients as the population with a high incidence of TPE, also called the typical population. However, it is notable that the utility of ADA fluctuated distinctly by stratified analysis, and if it did not satisfy any one condition (defined as the unconventional population), it was inferior to the T-SPOT assay. The unconventional population is frequently the focal point and has difficulties in diagnosis; as a result, the PF T-SPOT assay can provide powerful identification evidence for these patients.
There are several limitations in the current study. First, the entire study was performed in a single centre that specialized in TB. The geography, relative single control composition and aetiological attribution error and/or bias were incalculable. Second, we obtained the optimal cutoff for the PF T-SPOT.TB assay from ROC analysis in this training cohort, and its definite accuracy would need further validation. Finally, 38.1% of the clinically diagnosed patients lacked the aetiological basis due to objective factors such as no sputum or unsatisfactory sputum with the detection standard, which may bias the sputum detection rate.

Conclusion

In conclusion, neither ADA nor IGRA can be defined as definite proof of ruling in or out TPE, but they can be used as powerful reference tools for TPE diagnosis. The overall accuracy of the PF T-SPOT assay was equal to that of ADA for diagnosing TPE in our study. In addition, the PF T-SPOT assay can effectively discriminate TPE patients with low ADA and is extremely superior to ADA in unconventional TPE patients (age ≥ 45 yrs., female or BMI ≥ 22), indicating that the applied population is wider than that of ADA. The PF T-SPOT assay is an excellent choice to supplement ADA to diagnose TPE.

Acknowledgements

Not applicable

Ethics approval and consent to participate

We complied with the World Medical Association Declaration of Helsinki regarding ethical guidelines involving human subjects. The study protocol was approved by the Ethics Committee of the Beijing chest Hospital affiliated with Capital Medical University, China. We obtained written informed consent from all participants, and the consent of the participants below age 18 years were obtained from their guardian.

Consent for publication

Not applicable.

Competing interests

JZ is an Associate Editor at BMC Infectious Diseases. All other authors have no any possible competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver ( http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2021

BMC Infectious Diseases 1/2021 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin 

Bildnachweise